Investing

Viking Therapeutics : VKTX

VKTX

Stock Data

$30.00

$1.18 (3.78%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Viking Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. Its leading drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD with a novel approach, aiming for efficacy and safety. Viking is also advancing VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 for metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline aimed at addressing significant unmet medical needs.

All Viking Therapeutics Articles

32 Articles

Trey Thoelcke | Apr 10, 2026 at 8:25 AM EDT

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs.…

Trey Thoelcke | Apr 1, 2026 at 7:35 AM EDT

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual…

Trey Thoelcke | Feb 16, 2026 at 9:40 AM EST

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up…

Ian Cooper | Dec 23, 2025 at 8:58 AM EST

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Ian Cooper | Oct 31, 2025 at 10:18 AM EDT

3 Explosive Stocks With High Short Interest

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve…

Ian Cooper | Oct 30, 2025 at 9:40 AM EDT

3 Explosive Stocks With High Short Interest

High short interest can help investors identify potential high risks. And, it can also be a sign of a possible…

Rich Duprey | Aug 27, 2025 at 8:23 AM EDT

Eli Lilly’s Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race

A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of…

Rich Duprey | Aug 22, 2025 at 12:13 PM EDT

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in…

Joel South | Aug 19, 2025 at 9:08 AM EDT

Stock Market Live August 19: S&P 500 (VOO) Rally Still on Hold Pending Fed Talk

This article will be updated throughout the day, so check back often for more daily updates. It’s a pretty slow…

Rich Duprey | Apr 25, 2025 at 2:19 PM EDT

Eli Lilly Will Be the Next $1 Trillion Stock

Eli Lilly (NYSE:LLY | LLY Price Prediction) is a pharmaceutical titan with an $815 billion market cap, putting it on…

Trey Thoelcke | Feb 5, 2025 at 8:45 AM EST

Prediction: This Pharma Stock Will Be the Best Performer in 2025

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Rich Duprey | Jan 21, 2025 at 3:15 PM EST

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has been described as the best pure-play stock in artificial intelligence. The market…

Rich Duprey | Jan 15, 2025 at 9:06 AM EST

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly…

Rich Duprey | Sep 14, 2024 at 11:42 AM EDT

Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell

Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money”…